Faropenem is a potent and orally activebeta-lactamantibiotic. Faropenem demonstrates broad-spectrumin vitroantimicrobial activity against many gram-positive and -negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Faropenem is developed as an oral prodrug, faropenem medoxomil, for the research of respiratory tract infections^[1][2].

Faropenem is not active against methicillin-resistantStaphylococcus aureus, vancomycin-resistantEnterococcus faecium,Pseudomonas aeruginosaorStenotrophomonas maltophilia^[1].
Faropenem is against all isolates of B. anthracis. The MIC values ranged from ≤0.06 to >64 μg/liter, and the MIC₉₀ value is 0.5 μg/ml. The MIC₉₀ value for Faropenem is lower than that observed for other β-lactams, such as Meropenem, Amoxicillin-clavulanate, and Penicillin, for which the MIC₉₀ values are 4 μg/ml, 4 μg/ml, and 8 μg/ml, respectively^[2].

Faropenem ( i.p. at 24 h postchallenge at 4-, 6-, and 12-h intervals; 10, 20, 40, and 80 mg/kg/day; 14 days) demonstrates a high level of activity againstB. anthracisin the murine post-exposure prophylaxis inhalation model^[1].

285.32

C₁₂H₁₅NO₅S

106560-14-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.